Loading...
•
Dec 31, 2020
ADMA Biologics Q4 2020 Earnings Report
ADMA Biologics reported Q4 2020 financial results, showing revenue increase and a net loss.
Key Takeaways
ADMA Biologics reported a revenue of $14.0 million for the quarter ended December 31, 2020, representing a 16% increase compared to the same period in 2019. The company's net loss for the quarter was $19.4 million, or $(0.20) per share.
Total revenues for Q4 2020 were $14.0 million, a 16% increase compared to Q4 2019.
The revenue growth was favorably impacted by the continued commercial ramp up of the IVIG product portfolio.
Consolidated net loss for Q4 2020 was $19.4 million, or $(0.20) per basic and diluted share.
Year-end 2020 assets totaled $207.7 million.
ADMA Biologics
ADMA Biologics
Forward Guidance
ADMA Biologics provided first-time peak annual revenue guidance of $250 million or greater expected to be achieved in 2024 and additionally committed to reaching profitability no later than the first quarter of 2024.
Positive Outlook
- Anticipates Having 10 or More Plasma Collection Centers in Operation by 2024
- ADMA Biologics provided first-time peak annual revenue guidance of $250 million or greater expected to be achieved in 2024
- Committed to reaching profitability no later than the first quarter of 2024
- Significantly growing inventories to a year-end balance of $81.5 million
- Building on the momentum created by 2020’s achievements across all of our business segments
Challenges Ahead
- Unprecedented health and economic challenges due to the pandemic
- Increased cost of product revenue of $7.4 million
- Increases in selling, general and administrative expenses of $2.3 million
- A $0.5 million increase in research and development expenses
- Increased net loss additionally includes $1.1 million in higher plasma center operating expenses